市場調查報告書

末梢神經病變的全球市場:2020年-2027年

Global Peripheral Neuropathy Market - 2020-2027

出版商 DataM Intelligence 商品編碼 954261
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
末梢神經病變的全球市場:2020年-2027年 Global Peripheral Neuropathy Market - 2020-2027
出版日期: 2020年08月20日內容資訊: 英文
簡介

末梢神經病變,是身體的各部分與脊髓之間交換訊息的神經受損,或是因疾病產生的障礙。末梢神經病變的相關市場,由於人口增加,糖尿病患者增加,癌症化療藥的利用擴大,末梢神經病變相關意識的高漲等要素而繼續成長。2018年約有4億2,500萬個成人罹患糖尿病,預計2045年增加到6億2,900萬人。

本報告提供全球末梢神經病變市場調查,市場力學,產業分析,各類型,各治療法,各終端用戶,各地區的分析,競爭情形,企業簡介等資訊。

目錄

第1章 調查手法和範圍

  • 調查手法
  • 調查目的和範圍

第2章 市場定義和概要

第3章 摘要整理

  • 各類型市場
  • 各治療法市場
  • 各終端用戶市場
  • 地區市場

第4章 市場力學

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 影響分析
    • 市場機會

第5章 產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 法規分析
  • 價格分析

第6章 各類型的市場分析

  • 簡介
  • 市場規模和與前一年同期比較成長率分析
  • 市場魅力指數
    • 糖尿病性末梢神經病變*
    • 化療誘發性末梢神經病變
    • 特發性末梢神經病變
    • HIV/愛滋病相關末梢神經病變
    • 其他

第7章 各治療法的市場分析

  • 簡介
  • 市場規模和與前一年同期比較成長率分析
  • 市場魅力指數
    • 藥物治療*
    • 非藥物治療
    • 物理治療
    • 手術
    • 其他

第8章 各終端用戶的市場分析

  • 簡介
  • 市場規模和與前一年同期比較成長率分析
  • 市場魅力指數
    • 醫院*
    • 診所
    • 門診中心
    • 其他

第9章 各地區的市場分析

  • 簡介
    • 市場規模和與前一年同期比較成長率分析
    • 市場魅力指數
  • 北美
  • 歐洲
  • 南美
  • 亞太地區
  • 中東、非洲

第10章 競爭情形

  • 競爭模式
  • 市場定位/佔有率分析
  • 合併和收購分析

第11章 企業簡介

  • Averitas Pharma *
  • Cipla Laboratories
  • Merck and Co
  • Bristol Meyer Squibb
  • Reddy's Lab
  • Elli Lilly and Company
  • TEVA Pharmaceutical Industries
  • GlaxoSmithKline
  • Novartis AG
  • Abbott Laboratories
  • List is not exhaustive

第12章 主要調查結果

第13章 DataM Intelligence

目錄

Market Overview

Peripheral neuropathy is a disorder when nerves that convey messages to and from the mind and spinal line from the remainder of the body are harmed or ailing. The peripheral nerves make up an unpredictable system that interfaces the brain and spinal string to the muscles, skin, and inside organs. Peripheral nerves come out of the spinal line and are masterminded along lines in the body called dermatomes. When damage to a nerve will influence at least one dermatomes, which can be followed to specific regions of the body. Harm to these nerves interferes with correspondence between the cerebrum and different pieces of the body and can disable muscle development, and cause torment. The peripheral neuropathy market valued USD XX million in 2018 and it is expected to grow at a CAGR of XX% to reach USD XX million by 2027.

Market Dynamics:

The peripheral neuropathy market is driven by the rising population, growing commonness of diabetes, increasing chemotherapy medicines for cancer growth and rising mindfulness about fringe neuropathy. For instance, in 2018, roughly 425 million adults are suffering from diabetes, and by 2045 the number will ascend to 629 million. Individuals with diabetes are probably going to experience the ill effects of diabetes-instigated fringe neuropathy. General population studies have revealed that 7% to 18% of adults as of now have incessant neuropathic torment, where the detailed frequency is 1000 individuals for every year. Alone, in the UK the 26% of people with diabetes experience fringe neuropathic torment. These factors will drive the growth of peripheral neuropathy market in the forecast period.

Expanding mergers, acquisitions, and coordinated efforts by conspicuous players in the market encourage the organizations to enter the new market with inventive innovations. For instance, In June 2016, Merck & Co. acquired Afferent Pharmaceuticals to expand its pharmaceutical's business for the treatment of peripheral neurogenic conditions. The acquisition is for the development of medicines which can cure the disease. This factor will boost the business of the company since there is a small number of medicines and cures are present in the market for the treatment of peripheral neuropathy.

Peripheral neuropathy is perceived as the most continuous reason for non-awful removal in diabetic patients. The Neuropathy Association makes attention to peripheral neuropathy by furnishing patients with the essential assets, data, and apparatuses to manage to discover medicines. The collected data should be used in the development of pharmaceuticals and the treatment of peripheral neuropathy in the future.

In December 2019, InvaGen Pharmaceuticals, Inc., get final approval of for its Abbreviated New Drug Application (ANDA) for Pregabalin Capsules of 25mg to 300mg from the United States Food and Drug Administration (US FDA). Pregabalin capsules are indicated for the cure of neuropathic pain associated with diabetic peripheral neuropathy.

However, the stringent regulations regarding the side effects of the medicines use in the treatment and the misdiagnosed of peripheral neuropathy due to its complex array of symptoms will hinder the market growth in the forecast period.

Segment Analysis

The peripheral neuropathy market is segmented by type into Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, HIV/AIDS Associated Peripheral Neuropathy, and Others. The Diabetic Peripheral Neuropathy segment held the largest market share due to the increasing prevalence of diabetic peripheral neuropathy in youth who are suffering from diabetes. Diabetic neuropathy is a kind of nerve harm that can happen in the event that you have diabetes. High blood sugar will harm nerves all through the body. Diabetic neuropathy regularly harms nerves in the legs and feet. About 60% to 70% of all people with diabetes will eventually develop peripheral neuropathy, although not all suffer pain.

The Chemotherapy-induced Peripheral Neuropathy segment is expected to have positive market growth due to its use common in patients receiving anticancer treatment. In spite of the fact that the clinical introduction of chemotherapy-induced peripheral neuropathy can be comparable with the different classes of chemotherapeutic specialists, there are unpretentious contrasts, proposing that each class of medications may incite neuropathy by means of various systems. Different components have been proposed to underlie the turn of events and support of neuropathy. Most pharmacological operators created from preclinical trials have neglected to reduce the side effects.

HIV/AIDS Associated Peripheral Neuropathy side effects on patients as a rule experience incorporate consuming, firmness, prickling, shivering, and deadness or lost inclination in the toes and bottoms of the feet. The nerves in the fingers, hands, and wrists are additionally influenced. Generally extraordinary, torment over the lower legs could show increasingly serious nerve harm. According to the Foundation for Peripheral Neuropathy, it is estimated that about 33% of individuals with HIV/AIDS experience some fringe nerve harm. For patients with HIV/AIDS, peripheral neuropathy can be brought about by the infection itself, by specific medications utilized in the treatment of HIV/AIDS or different intricacies, or because of deft diseases.

Further, the market is also classified based on the treatment as Pharmacological Therapies, Non-Pharmacological Therapies, Physical Therapies, Surgery and others. Among these, the pharmacological therapies segment accounts for the highest market share due to the high usage primary in the treatment of peripheral neuropathy. A huge array of pharmacologic specialists, for example, nonsteroidal calming drugs (NSAIDs), antidepressants, analgesics, and antiepileptic drugs are utilized alone or in the blend for indicative administration. These medications bring about moderate adequacy, possible symptoms, and medication cooperation's.

Non-Pharmacological Therapies are used to decrease pain without the use of medicine. In this therapy, the treatments should be modified for the developmental stages, reflecting both the most problematic behavioral symptoms at that stage in time, and the patient's level of understanding.

Geographical Presentation

By region, the North America is dominating the peripheral neuropathy market and is expected to grow at the highest CAGR over the forecast period (2020-2027), due to the increasing prevalence of diabetes in the region. According to the Royal Pharmaceutical Society, in Canada 17.9% of the population reported chronic pain with neuropathic symptoms, however, a recent Canadian study has reported lower percentages. A study in the United State revealed that the prevalence rates for peripheral neuropathy determined by either clinical examination or self-reporting were 9.8% and 12.4%, respectively. The rising incidences of people suffering from various neuropathy problem in the region has fueled the growth of the market. The higher spending on the research and development activities for the treatment of peripheral neuropathy shall boost the market demand over the forecast period.

The Asia-Pacific region is expected to have large market share due to the increasing number of geriatric populations afflicted with chronic diseases like diabetes and cancer. The developing healthcare sector in the region has boosted the market. Countries like China and India has huge population, also the rise in the income level of middle class have given them capacity to spend them in the health care. These factors stimulate market growth over the forecasted period.

Competitive Analysis

The peripheral neuropathy market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. GlaxoSmithKline, Abbott Laboratories, Cipla Laboratories, Novartis AG, Merck and Co., Bristol Meyer Squibb, Reddy's Lab, Pfizer and Elli Lilly and Company, Eli Lilly are the leading market players with significant market share. The major players are using product development, novel product launches, market expansion, and product diversification strategies for holding their position in the market.

The companies are entering into the collaborations, mergers, strategic partnerships, and acquisitions for increase in the demand for the treatment of peripheral neuropathy across the globe. For instance,

  • In July 2020, The Food and Drug Administration (FDA) has approved Qutenza® a topical, non-systemic, non-opioid pain treatment delivered in the form of a patch, for the treatment of neuropathic pain associated with peripheral neuropathy of the feet.
  • In July 2020, Bristol Myers Squibb and bluebird bio reported the accommodation of their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for idecabtagene vicleucel , the organizations' investigational B-cell development antigen (BCMA)- coordinated illusory antigen receptor (CAR) T cell immunotherapy, for the treatment of grown-up patients with backslid and unmanageable numerous myeloma.
  • In February 2019, Teva Pharmaceutical Industries Ltd launched generic version of Sabril tablets to enter the US market. With more than 550 conventional prescriptions accessible, Teva has the biggest arrangement of FDA-endorsed nonexclusive items available and holds the main situation in first-to-document openings. The tablets has serious side effects include peripheral neuropathy.

Why Purchase the Report?

  • Visualize the composition of the peripheral neuropathy market products in terms of type, treatment, and end-user and highlighting the critical commercial assets and players.
  • Identify commercial opportunities in the peripheral neuropathy market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of peripheral neuropathy market-level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • *The peripheral neuropathy market report will provide access to approximately 29 market data tables, 45 figures, and 190 pages

Target Audience

  • Industry Investors/Investment Bankers
  • Suppliers/Buyers
  • Education & Research Institutes
  • Manufacturers
  • Research Professionals
  • Emerging Companies
  • Distributors

Table of Contents

1. Peripheral Neuropathy Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Peripheral Neuropathy Market - Market Definition and Overview

3. Peripheral Neuropathy Market - Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Treatment
  • 3.3. Market Snippet by End-User
  • 3.4. Market Snippet by Region

4. Peripheral Neuropathy Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Impact Analysis
    • 4.1.4. Opportunity

5. Peripheral Neuropathy Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis

6. Peripheral Neuropathy Market - By Type

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 6.3. Market Attractiveness Index, By Type
    • 6.3.1. Diabetic Peripheral Neuropathy *
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, US$ Mn, 2018-2027 and Y-o-Y Growth Analysis (%), 2019-2027
    • 6.3.2. Chemotherapy-induced Peripheral Neuropathy
    • 6.3.3. Idiopathic Peripheral Neuropathy Natural Colorants
    • 6.3.4. HIV/AIDS Associated Peripheral Neuropathy
    • 6.3.5. Others

7. Peripheral Neuropathy Market - By Treatment

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 7.3. Market Attractiveness Index, By Treatment
    • 7.3.1. Pharmacological Therapies*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, US$ Mn, 2018-2027 and Y-o-Y Growth Analysis (%), 2019-2027
    • 7.3.2. Non-Pharmacological Therapies
    • 7.3.3. Physical Therapies
    • 7.3.4. Surgery
    • 7.3.5. Others

8. Peripheral Neuropathy Market - By End-User

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 8.3. Market Attractiveness Index, By End User
    • 8.3.1. Hospitals *
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, USD Mn, 2018-2027 and Y-o-Y Growth Analysis (%), 2019-2027
    • 8.3.2. Clinics
    • 8.3.3. Ambulatory Centers
    • 8.3.4. Others

9. Peripheral Neuropathy Market - By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Peripheral Neuropathy Market Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Peripheral Neuropathy Market Company Profiles

  • 11.1. Averitas Pharma *
    • 11.1.1. Company Overview
    • 11.1.2. Form Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Cipla Laboratories
  • 11.3. Merck and Co
  • 11.4. Bristol Meyer Squibb
  • 11.5. Reddy's Lab
  • 11.6. Elli Lilly and Company
  • 11.7. TEVA Pharmaceutical Industries
  • 11.8. GlaxoSmithKline
  • 11.9. Novartis AG
  • 11.10. Abbott Laboratories
  • List is not exhaustive

12. Peripheral Neuropathy Market - Premium Insights

13. Peripheral Neuropathy Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us